GRACE PARK: Open Payments
NPI 1811363195 · FEDERAL WAY, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$703 in 35 payments from 13 companies in 2025. Trend: 2023 $631 · 2024 $808 · 2025 $703
Food & beverage: $703
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $192 |
| AstraZeneca Pharmaceuticals LP | 5 | $94 |
| Novo Nordisk Inc | 4 | $78 |
| ABBVIE INC. | 3 | $61 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Lilly USA, LLC | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Corcept Therapeutics | 1 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Dexcom, Inc. | 1 | $30 |
Products named: JARDIANCE, FARXIGA, GEMTESA, LINZESS, ZORYVE, Korlym, ZENPEP, Dexcom G6 Transmitter.
Industry payments across WA — which companies pay providers there.
